-

Scipher Medicine to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, today announced that Chief Financial Officer John Strumbos will participate in the virtual 11th Annual SVB Leerink Global Healthcare Conference, hosting investor meetings on Tuesday, February 15.

About Scipher Medicine®

Scipher Medicine, a precision immunology company matching each patient with their most effective therapy, believes that patients deserve simple answers to treatment options based on scientific data. Using Spectra™, our proprietary network medicine platform, we commercialize tests revealing a person’s unique molecular disease signature and match it to the most effective therapy, ensuring optimal treatment from day one. The patient molecular data generated from our tests further supports the discovery and development of novel and more effective therapeutics. We partner with leading payers, health care providers, and pharmaceutical companies to bring solutions to patients with autoimmune diseases. Visit http://www.sciphermedicine.com and follow Scipher Medicine on Twitter, Facebook, and LinkedIn.

Contacts

Media Relations
Molly Johnson
Director, Corporate Communications
PR@Scipher.com
518-423-5907

Investor Relations
John Strumbos, Ph.D., MBA
Chief Financial Officer
IR@scipher.com

Scipher Medicine


Release Summary
CFO John Strumbos will participate in the virtual 11th Annual SVB Leerink Global Healthcare Conference.
Release Versions

Contacts

Media Relations
Molly Johnson
Director, Corporate Communications
PR@Scipher.com
518-423-5907

Investor Relations
John Strumbos, Ph.D., MBA
Chief Financial Officer
IR@scipher.com

Social Media Profiles
More News From Scipher Medicine

Scipher Medicine and Maxymune Therapeutics Announce Strategic Collaboration to Accelerate Target Discovery in Autoimmune and Inflammatory Diseases

BURLINGTON, Mass.--(BUSINESS WIRE)--Scipher Medicine, a pioneer in network-based and AI-driven precision immunology, today announced a strategic collaboration with Maxymune Therapeutics, a biotechnology company focused on research and development of novel therapeutics for immunological disorders. Through this partnership, Maxymune will leverage Scipher’s platform to capitalize on Scipher’s target ranking capabilities across research and development programs. Under the terms of the agreement, Sc...

Scipher Medicine Launches ClinicalTrialRank.com: A Breakthrough AI Platform to Predict Clinical Trial Failure and Revolutionize Drug Development Investment Strategy

WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a leader in precision immunology, today announced the public launch of ClinicalTrialRank.com, an innovative artificial intelligence (AI) platform engineered to predict clinical trial failure with unprecedented accuracy. This cutting-edge capability is poised to transform drug development, enabling biopharmaceutical companies and investors to make more informed decisions and avoid investing billions in therapies destined to fail. ClinicalTrialRa...

Scipher and Savant Bio Partner to Build the Most Comprehensive Clinico-Genomic Dataset in Rheumatoid Arthritis

NEW YORK & WALTHAM, Mass.--(BUSINESS WIRE)--Scipher Medicine, a leader in precision immunology, and Savant Bio, a Roivant-backed health data infrastructure company, today announced an expanded strategic partnership to build the world’s most advanced clinicogenomic dataset in rheumatoid arthritis (RA). The collaboration aims to generate high-resolution insights to support academic research, clinical trial design, therapeutic strategy, and real-world evidence generation. The collaboration centers...
Back to Newsroom